Overview

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-nave Metastatic Castration-resistant Prostate Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-08-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Phase:

PHASE3

Details

Lead Sponsor:

Amgen

Treatments:

Abiraterone Acetate
cabazitaxel
Docetaxel